热门资讯> 正文
2025-05-08 04:46
Design Therapeutics (NASDAQ: DSGN) reported quarterly losses of $(0.31) per share which missed the analyst consensus estimate of $(0.28) by 10.71 percent. This is a 55 percent decrease over losses of $(0.20) per share from the same period last year.